EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage

Maria Pérez-Peiró, Paula Valentí-Serra, Blanca León-González, Coral Ampurdanés, Xavier Duran, José Yélamos iD, Esther Barreiro

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24032580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maria Pérez-Peiró und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group, IMIM-Hospital del Mar, Parc de Sal…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Sociedad Española de Neumología y Cirugía Torácica, Ministerio de Ciencia e Innovación de España.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In cancer, overactivation of poly (ADPribose) polymerases (PARP) plays a relevant role in DNA repair. We hypothesized that treatment with the PARP inhibitor rucaparib may reduce tumor burden via several biological mechanisms (apoptosis and oxidative stress) in mice. In lung tumors (LP07 lung adenocarcinoma) of mice treated/non-treated (control animals) with PARP inhibitor (rucaparib,150 mg/kg body weight/24 h for 20 day), PARP activity and expression, DNA damage, apoptotic nuclei, cell proliferation, and redox balance were measured using immunoblotting and immunohistochemistry. In lung tumors of rucaparib-treated mice compared to non-treated animals, tumor burden, PARP activity, and cell proliferation decreased, while DNA damage, TUNEL-positive nuclei, protein oxidation, and superoxide dismutase content (SOD)2 increased. In this experiment on lung adenocarcinoma, the pharmacological PARP inhibitor rucaparib elicited a significant improvement in tumor size, probably through a reduction in cell proliferation as a result of a rise in DNA damage and apoptosis. Oxidative stress and SOD2 also increased in response to treatment with rucaparib within the tumor cells of the treated mice. These results put the line forward to the contribution of PARP inhibitors to reduced tumor burden in lung adenocarcinoma. The potential implications of these findings should be tested in clinical settings of patients with lung tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsAnimalsMicePoly(ADP-ribose) Polymerase InhibitorsTumor BurdenCell Line, TumorPoly(ADP-ribose) PolymerasesOxidative StressDNA DamageApoptosisIndoles

Stichwörter der Autor:innen

DNA damage and apoptosisPARP activityPARP inhibitor rucaparibantioxidantscell proliferationlung adenocarcinoma experimental modelprotein oxidation

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesrucaparibIndoles

Autor:innen und Institutionen

  • Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group, IMIM-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universita…
  • Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.
  • Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)-Hospital del Mar, 08003 Barcelona, Spain.
  • Scientific, Statistics, and Technical Department, Hospital del Mar-IMIM, Parc de Salut Mar, 08003 Barcelona, Spain.

ORCID-Profile: José Yélamos

Förderung

  • Instituto de Salud Carlos III
  • Sociedad Española de Neumología y Cirugía Torácica
  • Ministerio de Ciencia e Innovación de España
  • European Social Fund “Investing in your future”
  • European Union and Consorcio Centro de Investigación Biomédica en Red (CIBERES) 2022
  • Spanish Ministry of Science and Innovation and European Union
  • Spanish Respiratory Society (SEPAR)
  • Spanish Ministry of Science and Innovation

Zitieren

APA

Pérez-Peiró, M., Valentí-Serra, P., León-González, B., Ampurdanés, C., Duran, X., Yélamos, J., & Barreiro, E. (2023). Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032580

Vancouver

Pérez-Peiró M, Valentí-Serra P, León-González B, Ampurdanés C, Duran X, Yélamos J, et al. Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032580

BibTeX
@article{PrezPeir2023,
  author = {Pérez-Peiró, Maria and Valentí-Serra, Paula and León-González, Blanca and Ampurdanés, Coral and Duran, Xavier and Yélamos, José and Barreiro, Esther},
  title = {Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24032580}
}
Kostenlos starten →